Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 10,144 GBX | -1.19% | +2.46% | -9.57% | |
| Dec. 05 | Altimmune open to partnerships, deals with drugmakers, says CEO | RE |
| Dec. 05 | Anything is possible |  |
Business Summary
- product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (3.1%).
Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
Number of employees : 83,500
Sales per Business
| GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Oncology
33.0
%
| 9,487 | 34.9 % | 11,878 | 33.0 % | +25.20% |
Cardiovascular, Renal and Metabolism
20.7
%
| 5,831 | 21.4 % | 7,459 | 20.7 % | +27.91% |
Rare Disease
15.9
%
| 2,232 | 8.2 % | 5,726 | 15.9 % | +156.51% |
Respiratory and Immunology
13.0
%
| 4,387 | 16.1 % | 4,680 | 13.0 % | +6.67% |
Vaccines and Immune Therapies
10.7
%
| - | - | 3,845 | 10.7 % | - |
Other Medicines
3.7
%
| 1,721 | 6.3 % | 1,319 | 3.7 % | -23.35% |
Collaboration
3.1
%
| 637 | 2.3 % | 1,098 | 3.1 % | +72.45% |
Sales per region
| GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
United States
39.0
%
| 8,760 | 32.2 % | 14,027 | 39.0 % | +60.13% |
China
12.9
%
| 4,364 | 16.0 % | 4,662 | 12.9 % | +6.83% |
Japan
9.0
%
| 2,469 | 9.1 % | 3,236 | 9.0 % | +31.09% |
United Kingdom
7.0
%
| 2,359 | 8.7 % | 2,530 | 7.0 % | +7.25% |
Other Rest of Europe
6.1
%
| 1,417 | 5.2 % | 2,197 | 6.1 % | +55.02% |
Other Asia, Africa and Australasia
5.4
%
| 1,730 | 6.4 % | 1,953 | 5.4 % | +12.92% |
Germany
4.3
%
| 1,080 | 4.0 % | 1,544 | 4.3 % | +42.91% |
Sweden
3.9
%
| 1,688 | 6.2 % | 1,397 | 3.9 % | -17.25% |
Other Americas
2.6
%
| 875 | 3.2 % | 954 | 2.6 % | +9.05% |
Canada
2.6
%
| 561 | 2.1 % | 947 | 2.6 % | +68.63% |
France
2.5
%
| 665 | 2.4 % | 899 | 2.5 % | +35.08% |
Spain
1.7
%
| 420 | 1.5 % | 599 | 1.7 % | +42.56% |
Italy
1.7
%
| 420 | 1.5 % | 597 | 1.7 % | +42.23% |
Australia
1.3
%
| 398 | 1.5 % | 464 | 1.3 % | +16.55% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 49 | 2021 |
Pam Cheng
COO | Chief Operating Officer | 52 | 2015 |
Katarina Ageborg
CMP | Compliance Officer | - | 1997 |
Jeffrey Pott
CMP | Compliance Officer | - | 1994 |
Regina Danielson
CTO | Chief Tech/Sci/R&D Officer | 59 | - |
Helen MacPhee
PRN | Corporate Officer/Principal | 63 | - |
| Treasurer | 58 | - | |
| Corporate Officer/Principal | - | 2017 | |
Tyrell J. Rivers
PRN | Corporate Officer/Principal | 50 | 2013 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 64 | 2017 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 58 | 2013 |
Philip Broadley
BRD | Director/Board Member | 62 | 2017 |
| Director/Board Member | 67 | 1999 | |
Marc Dunoyer
PRN | Corporate Officer/Principal | 71 | 2013 |
Andreas Rummelt
BRD | Director/Board Member | 66 | 2021 |
Michel Demaré
CHM | Chairman | 67 | 2019 |
Pascal Soriot
CEO | Chief Executive Officer | 63 | 2012 |
Deborah DiSanzo
BRD | Director/Board Member | 63 | 2017 |
Aradhana Sarin
DFI | Director of Finance/CFO | 49 | 2021 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,549,926,211 | 1,495,104,073 ( 96.46 %) | 0 | 96.46 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
| 18,750,000 | 75.00% | 1,052,603,250 $ | |
CELLECTIS S.A. 28.79% | 16,000,000 | 28.79% | 15,220,800 $ |
NIOX GROUP PLC 16.90% | 71,059,999 | 16.90% | 56,823,839 $ |
INNATE PHARMA 9.28% | 7,485,500 | 9.28% | 17,960,634 $ |
| 32,100,518 | 9.07% | 659,096,824 $ | |
ADC THERAPEUTICS SA 4.97% | 4,011,215 | 4.97% | 2,807,851 $ |
| 3,584,230 | 3.63% | 849,463 $ | |
| 884,956 | 2.20% | 83,186 $ |
Company contact information
AstraZeneca PLC
2 Kingdom Street Paddington
W2 6BD, London
+44 20 3749 5000
http://www.astrazeneca.co.uk
Group companies
| Name | Category and Sector |
|---|---|
AstraZeneca AB
|
Commercial Services - Miscellaneous Commercial Services
|
Health Technology - Pharmaceuticals: Major
| |
AstraZeneca UK Ltd.
|
Health Technology - Pharmaceuticals: Major
|
R&Q Beta Co. Plc
|
Finance - Insurance Brokers/Services
|
AstraZeneca India Pvt Ltd.
|
Health Technology - Pharmaceuticals: Major
|
Astrazeneca Holdings BV
|
-
|
AstraZeneca Share Trust Ltd.
|
Commercial Services - Miscellaneous Commercial Services
|
AstraZeneca Employee Share Trust Ltd.
|
Commercial Services - Miscellaneous Commercial Services
|
Astrazeneca Treasury BV
|
-
|
Sector
Sales per Business
Sales per region
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
127.81USD
Average target price
165.33USD
Spread / Average Target
+29.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.57% | 198 B $ | |
| +60.77% | 529 B $ | |
| +46.50% | 444 B $ | |
| -10.25% | 382 B $ | |
| -4.25% | 269 B $ | |
| -10.54% | 255 B $ | |
| -13.61% | 231 B $ | |
| +1.76% | 200 B $ | |
| -43.23% | 164 B $ | |
| +3.13% | 145 B $ |
- Stock
- Equities
- Stock AstraZeneca PLC - London Stock Exchange
- Company AstraZeneca PLC
